Clinical trial
Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents…
NCT00485459 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00485459 |
|---|---|
| Title | Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD |
| Official title | Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With Attention-Deficit/Hyperactivity Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | Atomoxetine Hydrochloride, Placebo |
| Enrollment | 106 |
| Start date | Feb 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Jun 13, 2007 |
| Last update posted | Jun 13, 2007 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: